<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435174</url>
  </required_header>
  <id_info>
    <org_study_id>IN-US-259-0123, HUM00051141</org_study_id>
    <nct_id>NCT01435174</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients</brief_title>
  <official_title>Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      End-stage renal disease (ESRD) patients often develop cardiovascular complications, and
      cardiovascular disease is the leading cause of death in this population. Ranolazine's ability
      to treat angina without reducing heart rate or blood pressure makes it an important option
      for ESRD patients. The hemodialysis clearance of ranolazine is unknown. A single-dose
      pharmacokinetic study is needed to characterize ranolazine and its metabolites in ESRD
      patients on and off hemodialysis. Results of the proposed study will provide initial dosing
      estimates for a follow-up, multiple-dose pharmacokinetic study in this population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters of Ranolazine</measure>
    <time_frame>At hours post-dose: 0, 2, 4, 8, 12, 15, 18, 20, 22, 23, 26, 30, 65</time_frame>
    <description>Peak Plasma Concentration (Cmax) with a 500 mg dose of ranolazine</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>End-stage Renal Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>A single dose of two oral ranolazine extended release 500 mg tablets</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pharmacokinetic Blood and Dialysate Sampling</intervention_name>
    <description>Blood samples collected to assess ranolazine plasma and dialysate concentrations.</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
    <other_name>PK sampling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>QT Interval</intervention_name>
    <description>Calculation of a QT interval will be performed throughout subject participation.</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
    <other_name>QT interval calculation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-74 years of age

          -  Within 50% of ideal body weight and greater than 40 kg

          -  Chronic kidney disease (CKD) stage 5 receiving maintenance hemodialysis for at least 3
             months

          -  Native kidney estimated glomerular filtration rate(GFR) &lt; 10 mL/min

          -  No concurrent illness or evidence of infection

          -  Able to give informed consent

        Exclusion Criteria:

          -  QTc interval &gt; 470 msec at echocardiogram (ECG) obtained within the last 6 months

          -  Concomitant QT-prolonging drugs, major P-gp inhibitors, and CYP3A4 inducers and
             inhibitors including: cyclosporine, rifampin, rifabutin, rifapentine, phenobarbital,
             phenytoin, carbamazepine, St. John's Wort, ketoconazole, itraconazole, clarithromycin,
             nefazodone, nelfinavir, ritonavir, indinavir, saquinavir, quinidine, dofetilide,
             sotalol, amiodarone, erythromycin, thioridazine, ziprasidone, haloperidol,
             trimethoprim/sulfamethoxazole, ciprofloxacin, norfloxacin, levofloxacin, moxifloxacin

          -  Pre-study hemoglobin &lt; 9.5 g/dL

          -  Plasma albumin &lt; 2.5 g/dL

          -  Liver disease - exclude subjects with a Child Pugh score of C or higher

          -  Positive pregnancy test

          -  Breastfeeding

          -  Allergy to ranolazine

          -  Participating in another investigational study

          -  Hepatitis B infection due to dialysis isolation requirements

          -  Unstable blood pressure control

          -  Need for routine large fluid removal during dialysis (&gt; 4L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce A Mueller, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2011</study_first_posted>
  <results_first_submitted>May 21, 2014</results_first_submitted>
  <results_first_submitted_qc>May 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2014</results_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Bruce A. Mueller</investigator_full_name>
    <investigator_title>Associate Dean of Academic Affairs</investigator_title>
  </responsible_party>
  <keyword>ranolazine</keyword>
  <keyword>end-stage renal disease</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine</title>
          <description>End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
Ranolazine: A single dose of two oral ranolazine extended release 500 mg tablets
Pharmacokinetic Blood and Dialysate Sampling: Blood samples collected to assess ranolazine plasma and dialysate concentrations.
QT Interval: Calculation of a QT interval will be performed throughout subject participation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients 18 to 74 with chronic kidney disease stage 5 receiving 3 times weekly maintenance hemodialysis for at least 3 months were considered for study inclusion. Patients had to weigh &gt;40 kilograms, be within 50-150% of their ideal body weight, have an eGFR of &lt;10 mL/min, have no evidence of infection, and be able to give informed consent.</population>
      <group_list>
        <group group_id="B1">
          <title>Ranolazine</title>
          <description>End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
Ranolazine: A single dose of two oral ranolazine extended release 500 mg tablets
Pharmacokinetic Blood and Dialysate Sampling: Blood samples collected to assess ranolazine plasma and dialysate concentrations.
QT Interval: Calculation of a QT interval will be performed throughout subject participation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="20" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters of Ranolazine</title>
        <description>Peak Plasma Concentration (Cmax) with a 500 mg dose of ranolazine</description>
        <time_frame>At hours post-dose: 0, 2, 4, 8, 12, 15, 18, 20, 22, 23, 26, 30, 65</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
Ranolazine: A single dose of two oral ranolazine extended release 500 mg tablets
Pharmacokinetic Blood and Dialysate Sampling: Blood samples collected to assess ranolazine plasma and dialysate concentrations.
QT Interval: Calculation of a QT interval will be performed throughout subject participation.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of Ranolazine</title>
          <description>Peak Plasma Concentration (Cmax) with a 500 mg dose of ranolazine</description>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine</title>
          <description>End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
Ranolazine: A single dose of two oral ranolazine extended release 500 mg tablets
Pharmacokinetic Blood and Dialysate Sampling: Blood samples collected to assess ranolazine plasma and dialysate concentrations.
QT Interval: Calculation of a QT interval will be performed throughout subject participation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Potassium with EKG Changes</sub_title>
                <description>High potassium was determined to be due to needing dialysis and unlikely related to the administration of ranolazine. The subject admitted to drinking more than usual (including fruit juice) and not following renal diet over the weekend.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bruce A. Mueller</name_or_title>
      <organization>University of Michigan College of Pharmacy</organization>
      <phone>7346154578</phone>
      <email>muellerb@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

